News

Press Release Sep 01 2026 FORE Biotherapeutics Announces Positive Outcome from First Planned Interim Efficacy Analysis from FORTE Basket Study Evaluating Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions Read more

Press Release Jul 07 2026 FORE Biotherapeutics Announces Closing of Upsized $67.4 Million Series D-2 Extension Financing and Highlights Recent Plixorafenib Achievements Read more

Press Release May 12 2026 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Press Release Apr 01 2026 FORE Biotherapeutics Receives Breakthrough Therapy Designation for Plixorafenib Read more

Press Release Nov 04 2025 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Press Release Sep 24 2025 FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors Read more

Press Release Sep 12 2025 FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting Read more

Press Release Aug 27 2025 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Press Release May 27 2025 FORE Biotherapeutics to Participate in the Jefferies Global Healthcare Conference Read more